AI-powered rare disease diagnosis market seen reaching $7.08B by 2030

The Business Research Company says the AI-powered rare disease diagnosis market is set to surge from $2.56 billion in 2026 to $7.08 billion by 2030, driven by genetic testing, personalized medicine and faster clinical decision-making. North America led the market in 2025, while Asia-Pacific is expected to grow the fastest.

Why it matters: - AI tools are shortening the path to diagnosing rare diseases, where delays and missed cases can worsen outcomes. - The market’s projected rise signals growing demand for diagnostic systems that combine genetic, clinical and imaging data. - The report frames rare disease diagnosis as a major growth area for personalized medicine and data-driven care.

What happened: - The Business Research Company released a market report on the global AI-powered rare disease diagnosis sector. - The market is projected to grow from $1.99 billion in 2025 to $2.56 billion in 2026. - The report forecasts the market will reach $7.08 billion by 2030. - The report cites a 28.9% compound annual growth rate across both the near-term and forecast periods. - The report covers regions including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - A free sample report is available online. - The full market report is also available.

The details: - The report says historical growth has been driven by difficulty diagnosing rare diseases, wider access to genetic testing, higher investment in rare disease research, increased use of healthcare data analytics and early adoption of AI diagnostic tools. - The report expects future growth to be supported by stronger use of personalized medicine, broader AI-supported clinical decision-making, more genomic sequencing in diagnostics, higher investment in rare disease screening and demand for faster diagnostic workflows. - Emerging trends include better AI-based pattern recognition, more genomic data analytics platforms, integration of multiple patient data sources, growth in cloud-enabled diagnostic solutions and a stronger push for early and precise diagnosis. - AI-powered rare disease diagnosis uses machine learning and related algorithms to analyze genetic profiles, clinical records and imaging results. - The report says these tools can uncover patterns traditional diagnostic methods may miss. - The report links market expansion to the rising prevalence of autoimmune disorders. - The Mayo Clinic reported in January 2025 that about 15 million people have one or more of 105 identified autoimmune diseases. - In 2025, North America held the largest share of the global market. - The Asia-Pacific region is expected to post the fastest growth during the forecast period. - The report’s 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables.

Between the lines: - The report points to a broader shift in diagnostics from isolated test results to integrated, AI-assisted interpretation of patient data. - The focus on genomic sequencing and cloud-based tools suggests the market is moving toward more scalable and data-intensive diagnostic platforms. - The autoimmune disease example shows how a broader disease burden can expand demand for rare-disease-adjacent AI tools, even beyond truly rare conditions.

What's next: - Market growth will likely track adoption of AI in clinical decision support, genomics and rare disease screening programs. - The fastest growth may come from regions where healthcare systems are scaling digital diagnostics and data infrastructure. - The report’s forecast suggests continued investment in tools aimed at earlier and more precise diagnosis through 2030.